5-Iodo-A-85380, an α4β2 Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors

In an effort to develop selective radioligands for in vivo imaging of neuronal nicotinic acetylcholine receptors (nAChRs), we synthesized 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine (5-iodo-A-85380) and labeled it with 125I and123I. Here we present the results of experiments characterizing this radioiodinated ligand in vitro. The affinity of 5-[125I]iodo-A-85380 for α4β2 nAChRs in rat and human brain is defined by K d values of 10 and 12 pM, respectively, similar to that of epibatidine (8 pM). In contrast to epibatidine, however, 5-iodo-A-85380 is more selective in binding to the α4β2 subtype than to other nAChR subtypes. In rat adrenal glands, 5-iodo-A-85380 binds to nAChRs containing α3 and β4 subunits with 1/1000th the affinity of epibatidine, and exhibits 1/60th and 1/190th the affinity of epibatidine at α7 and muscle-type nAChRs, respectively. Moreover, unlike epibatidine and cytisine, 5-[125I]iodo-A-85380 shows no binding in any brain regions in mice homozygous for a mutation in the β2 subunit of nAChRs. Binding of 5-[125I]iodo-A-85380 in rat brain is reversible, and is characterized by high specificity and a slow rate of dissociation of the receptor–ligand complex (t 1/2 for dissociation ∼2 h). These properties, along with other features observed previously in in vivo experiments (low toxicity, rapid penetration of the blood-brain barrier, and a high ratio of specific to nonspecific binding), suggest that this compound, labeled with 125I or 123I, is superior to other radioligands available for in vitro and in vivo studies of α4β2 nAChRs, respectively.

[1]  J. Changeux,et al.  Identification of Four Classes of Brain Nicotinic Receptors Using β2 Mutant Mice , 1998, The Journal of Neuroscience.

[2]  S. Rogers,et al.  Neuronal Nicotinic Receptor Expression in Sensory Neurons of the Rat Trigeminal Ganglion: Demonstration of α3β4, a Novel Subtype in the Mammalian Nervous System , 1996, The Journal of Neuroscience.

[3]  Felix Franks,et al.  In-Vitro Characterization of mCerulean3_mRuby3 as a Novel FRET Pair with Favorable Bleed-Through Characteristics , 2019, Biosensors.

[4]  P. Bougis,et al.  Selective loss of binding sites for the iodinated alpha-neurotoxin I from Naja mossambica mossambica venom upon enzymatic deglycosylation of Torpedo electric organ membranes. , 1988, European Journal of Biochemistry.

[5]  D. Donnelly-roberts,et al.  (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization. , 1994, The Journal of pharmacology and experimental therapeutics.

[6]  J. Wroblewski,et al.  Rat alpha3/beta4 subtype of neuronal nicotinic acetylcholine receptor stably expressed in a transfected cell line: pharmacology of ligand binding and function. , 1998, Molecular pharmacology.

[7]  S. Arneric,et al.  Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. , 1995, Life sciences.

[8]  E. London,et al.  Radiosynthesis and preliminary evaluation of 5-[123/125I]iodo-3-(2(S)-azetidinylmethoxy)pyridine: a radioligand for nicotinic acetylcholine receptors. , 1999, Nuclear medicine and biology.

[9]  J M Links,et al.  In vivo imaging of brain nicotinic acetylcholine receptors with 5-[123I]iodo-A-85380 using single photon emission computed tomography. , 1998, Life sciences.

[10]  S. Wonnacott,et al.  Agonist-induced up-regulation of alpha4beta2 nicotinic acetylcholine receptors in M10 cells: pharmacological and spatial definition. , 1998, Molecular pharmacology.

[11]  R. Dannals,et al.  5-[I-125/123]lodo-3(2(S)-azetidinylmethoxy)pyridine, a radioiodinated analog of A-85380 for in vivo studies of central nicotinic acetylcholine receptors. , 1998, Life sciences.

[12]  E. London,et al.  Synthesis and evaluation of N-[11C]methylated analogues of epibatidine as tracers for positron emission tomographic studies of nicotinic acetylcholine receptors. , 1998, Journal of medicinal chemistry.

[13]  Mary Ann Moran,et al.  Synthesis and Evaluation , 1986 .

[14]  Michele Zoli,et al.  Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain , 1995, Nature.

[15]  A. C. Collins,et al.  Differential agonist inhibition identifies multiple epibatidine binding sites in mouse brain. , 1998, Journal of Pharmacology and Experimental Therapeutics.

[16]  P. Adams,et al.  Characterization of Human Recombinant Neuronal Nicotinic Acetylcholine Receptor Subunit Combinations α2β4, α3β4 and α4β4 Stably Expressed in HEK293 Cells , 1998 .

[17]  K. Kellar,et al.  [3H]epibatidine labels nicotinic receptors in rat brain: an autoradiographic study. , 1995, The Journal of pharmacology and experimental therapeutics.

[18]  E. London,et al.  In vivo studies with [125I]5‐I‐A‐85380, a nicotinic acetylcholine receptor radioligand , 1998, Neuroreport.

[19]  K. Kellar,et al.  Differential Regulation of Neuronal Nicotinic Receptor Binding Sites Following Chronic Nicotine Administration , 1997, Journal of neurochemistry.

[20]  K. Kellar,et al.  [3H]cytisine binding to nicotinic cholinergic receptors in brain. , 1991, Molecular pharmacology.

[21]  D. Wong,et al.  Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon. , 1999, Nuclear medicine and biology.

[22]  J K Lynch,et al.  Neuronal nicotinic acetylcholine receptors as targets for drug discovery. , 1997, Journal of medicinal chemistry.

[23]  J. Juiz,et al.  Differential Expression of α-Bungarotoxin-Sensitive Neuronal Nicotinic Receptors in Adrenergic Chromaffin Cells: A Role for Transcription Factor Egr-1 , 1997, The Journal of Neuroscience.

[24]  J S Fowler,et al.  Fluoro-norchloroepibatidine: preclinical assessment of acute toxicity. , 1997, Nuclear medicine and biology.

[25]  D. Donnelly-roberts,et al.  Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. , 1996, Journal of medicinal chemistry.

[26]  D. Donnelly-roberts,et al.  Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. , 1998, Science.

[27]  R. Maue,et al.  Nerve growth factor increases nicotinic ACh receptor gene expression and current density in wild-type and protein kinase A-deficient PC12 cells , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[28]  P. Bougis,et al.  Characterization of elapidae snake venom components using optimized reverse-phase high-performance liquid chromatographic conditions and screening assays for alpha-neurotoxin and phospholipase A2 activities. , 1986, Biochemistry.

[29]  E. London,et al.  Synthesis of a radioiodinated analog of epibatidine : (±)-exo-2-(2-iodo-5-pyridyl)-7-azabicyclo[2.2.1]heptane for in vitro and in vivo studies of nicotinic acetylcholine receptors , 1997 .

[30]  E. London,et al.  [125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors. , 1997, The Journal of pharmacology and experimental therapeutics.

[31]  R. Lukas,et al.  Similarity Between Rat Brain Nicotinic α‐Bungarotoxin Receptors and Stably Expressed α‐Bungarotoxin Binding Sites , 1996 .

[32]  S. Heinemann,et al.  The expression of nicotinic acetylcholine receptors by PC12 cells treated with NGF , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[33]  R. Glennon,et al.  Epibatidine: A Very High Affinity Nicotine-Receptor Ligand. , 1995 .

[34]  K. Kellar,et al.  Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. , 1995, Molecular pharmacology.

[35]  S. Rogers,et al.  A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. , 1992, Molecular pharmacology.

[36]  E. London,et al.  2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. , 1998, Journal of medicinal chemistry.

[37]  D. Donnelly-roberts,et al.  A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: In Vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand , 1996, Neuropharmacology.

[38]  A. Nordberg,et al.  Laminar distribution of nicotinic receptor subtypes in human cerebral cortex as determined by [3H](-)nicotine, [3H]cytisine and [3H]epibatidine in vitro autoradiography , 1998, Neuroscience.

[39]  P. Lippiello,et al.  The binding of L-[3H]nicotine to a single class of high affinity sites in rat brain membranes. , 1986, Molecular pharmacology.

[40]  R. Boyd,et al.  Evidence for spare nicotinic acetylcholine receptors and a beta 4 subunit in bovine adrenal chromaffin cells: studies using bromoacetylcholine, epibatidine, cytisine and mAb35. , 1997, The Journal of pharmacology and experimental therapeutics.